ERG
ERG (Transcriptional regulator ERG) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Prostate cancer, Non-Hodgkin lymphoma and 4 more.
Overview
Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes genetic literature 0.61, literature 1.00, genetic association 0.03, somatic mutation 0.83, animal model 0.57). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Angiosarcoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ERG (Transcriptional regulator ERG) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Prostate cancer, Non-Hodgkin lymphoma and 4 more.
- 1 · What it is
ERG (Transcriptional regulator ERG) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Prostate cancer, Non-Hodgkin lymphoma and 4 more.
- 2 · What goes wrong in cancer
Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure.
- 3 · How drugs use it
No product in this corpus aims at ERG yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:3446 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P11308 (protein name, function text, keywords and locations (REST API)); CIViC gene ERG (1 evidence items, 0 assertions, 1 variants; diseases: B-lymphoblastic Leukaemia/lymphoma (GraphQL API, CC0)); Open Targets ENSG00000157554 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: prostate cancer 0.58, sarcoma 0.67, neuroendocrine neoplasm 0.52, acute lymphoblastic leukaemia 0.54, non-Hodgkin lymphoma 0.56, leukaemia 0.56 (GraphQL API, CC0)); IntOGen ERG (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure. Location: Nucleus; Cytoplasm (UniProt). Locus 21q22.2 (HGNC).
- Sarcomas: Open Targets association 0.67 with sarcoma (MONDO_0005089)
- Prostate cancer: Open Targets association 0.58 with prostate cancer (MONDO_0008315)
- Non-Hodgkin lymphoma: Open Targets association 0.56 with non-Hodgkin lymphoma (MONDO_0018908)
- Leukaemia: Open Targets association 0.56 with leukaemia (MONDO_0005059)
- Neuroendocrine tumours: Open Targets association 0.52 with neuroendocrine neoplasm (MONDO_0019496)
- Acute lymphoblastic leukaemia: Open Targets association 0.54 with acute lymphoblastic leukaemia (MONDO_0004967); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ERG" OR ABSTRACT:"ERG" OR TITLE:"ETS transcription factor ERG" OR ABSTRACT:"ETS transcription factor ERG" OR TITLE:"Transcriptional regulator ERG" OR ABSTRACT:"Transcriptional regulator ERG" OR TITLE:"erg-3" OR ABSTRACT:"erg-3" OR TITLE:"p55" OR ABSTRACT:"p55") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ERG, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZMYM2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetPLCG1
Shares Angiosarcoma, Leukaemia (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST).
- TargetGATA3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, CIViC.
- TargetETV6
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST), Acute lymphoblastic leukaemia.
- TargetPAX5
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, CIViC.
- TargetAFF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetNT5C2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, CIViC.
- TargetSUZ12
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST), IntOGen.